サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1764118

クリプトコッカス症治療市場-世界の産業規模、シェア、動向、機会、予測、治療別、流通チャネル別、地域別、競合別、2020～2030年

Cryptococcosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By Distribution Channel, By Region and Competition, 2020-2030F

出版日
ページ情報
英文 189 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.05円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

クリプトコッカス症治療市場-世界の産業規模、シェア、動向、機会、予測、治療別、流通チャネル別、地域別、競合別、2020～2030年
出版日: 2025年06月30日
発行: TechSci Research
ページ情報: 英文 189 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

クリプトコッカス症治療の世界市場は、2024年には53億4,000万米ドルと評価され、2030年には72億8,000万米ドルに達すると予測され、予測期間中のCAGRは5.27%です。

クリプトコッカス症は、主に肺と中枢神経系を侵し、鳥の糞で汚染された土壌によく見られる真菌の胞子を吸入することで発症します。HIV/AIDS、臓器移植、がん治療などの免疫抑制状態の罹患率の上昇により、この感染症に対する感受性が著しく高まっています。その結果、抗真菌治療に対する需要が高まっています。市場の成長をさらに支えているのは、先進的な治療法、製剤の改良、併用治療に関する継続的な研究です。製薬会社、研究機関、公開医療機関の戦略的提携は、技術革新を推進し、効果的な治療法へのアクセスを拡大し、最終的に生存率と患者の転帰を改善する上で重要な役割を果たしています。

市場概要
予測期間 2026～2030年
市場規模：2024年 53億4,000万米ドル
市場規模：2030年 72億8,000万米ドル
CAGR：2025～2030年 5.27%
急成長セグメント フルシトシン
最大市場 北米

市場促進要因

免疫不全患者の増加

主要市場課題

真菌感染症の複雑性

主要市場動向

技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のクリプトコッカス症治療市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 治療別（アムホテリシンB、フルシトシン、フルコナゾール、その他）
    • 流通チャネル別（病院、薬局、専門クリニック、その他）
    • 地域別
    • 企業別（市場上位5社のシェア）
  • 市場マップ
    • 治療別
    • 流通チャネル別
    • 地域別

第6章 北米のクリプトコッカス症治療市場展望

  • 市場規模・予測
  • 市場シェア・予測

第7章 欧州のクリプトコッカス症治療市場展望

  • 市場規模・予測
  • 市場シェア・予測

第8章 アジア太平洋のクリプトコッカス症治療市場展望

  • 市場規模・予測
  • 市場シェア・予測

第9章 南米のクリプトコッカス症治療市場展望

  • 市場規模・予測
  • 市場シェア・予測

第10章 中東・アフリカのクリプトコッカス症治療市場展望

  • 市場規模・予測
  • 市場シェア・予測

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併と買収
  • 治療開始

第13章 競合情勢

  • Astellas Pharma Inc
  • Bristol-Myers Squibb Company
  • Glenmark Pharmaceuticals
  • Janssen BIoTech Inc.（Johnson & Johnson Services, Inc.）
  • Novartis AG
  • Pfizer Inc
  • Asahi Kasei Pharma
  • Sigmapharm Laboratories LLC

第14章 戦略的提言

第15章 調査会社について・免責事項

目次
Product Code: 15909

The Global Cryptococcosis Therapeutics Market was valued at USD 5.34 billion in 2024 and is anticipated to reach USD 7.28 billion by 2030, growing at a CAGR of 5.27% during the forecast period. Cryptococcosis, primarily affecting the lungs and central nervous system, arises from the inhalation of fungal spores commonly found in soil contaminated by bird droppings. The rising incidence of immunosuppressive conditions-such as HIV/AIDS, organ transplantation, and cancer therapies-has significantly increased the susceptibility to this infection. Consequently, demand for antifungal treatments is rising. Market growth is further supported by ongoing research into advanced therapies, improved drug formulations, and combination treatments. Strategic collaborations among pharmaceutical companies, research institutions, and public health entities are instrumental in driving innovation and expanding access to effective therapies, ultimately improving survival rates and patient outcomes.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 5.34 Billion
Market Size 2030USD 7.28 Billion
CAGR 2025-20305.27%
Fastest Growing SegmentFlucytosine
Largest MarketNorth America

Key Market Drivers

Increasing Prevalence of Immunocompromised Conditions

The growing number of individuals with compromised immune systems has become a significant driver of the cryptococcosis therapeutics market. HIV/AIDS continues to be a major risk factor, particularly in low-resource settings with limited access to antiretroviral therapy. According to UNAIDS, nearly 39 million individuals were living with HIV globally in 2023. This group remains highly susceptible to opportunistic infections like cryptococcosis. Additionally, advances in medical procedures such as organ transplantation are contributing to the expanding immunosuppressed population. Over 157,000 solid organ transplants were conducted globally in 2022, with recipients requiring lifelong immunosuppressive therapy-thereby increasing their risk of fungal infections. As this vulnerable demographic grows, the need for effective antifungal therapies becomes increasingly urgent.

Key Market Challenges

Complexity of Fungal Infections

Cryptococcosis presents inherent treatment challenges due to the complex biology of fungal pathogens. Unlike bacteria, fungi share many cellular features with human cells, limiting drug targets and raising concerns over toxicity. Cryptococcus neoformans, the causative agent, possesses defense mechanisms such as robust cell walls, protective capsules, and biofilm formation that hinder treatment efficacy. Antifungal resistance, limited therapeutic options, and poor diagnostic capabilities-especially in resource-limited settings-further complicate management. Current treatments, including amphotericin B and flucytosine, often require intravenous administration and are associated with considerable side effects. Treating cryptococcal meningitis is particularly challenging due to the blood-brain barrier, which restricts drug penetration. These barriers not only impact clinical outcomes but also discourage pharmaceutical innovation due to high development costs and regulatory hurdles.

Key Market Trends

Technological Advancements

Technological progress is shaping the future of the cryptococcosis therapeutics market by enhancing diagnostic accuracy and therapeutic delivery. Advanced molecular diagnostic tools like PCR assays and next-generation sequencing are improving early detection and guiding timely intervention. Point-of-care diagnostic kits are also gaining traction, particularly in low-resource areas. In treatment, innovations such as liposomal formulations of amphotericin B are reducing toxicity while maintaining efficacy. Nanotechnology and targeted delivery systems are being explored to enhance drug bioavailability and CNS penetration. Moreover, artificial intelligence and bioinformatics are accelerating antifungal drug discovery. These developments are addressing long-standing therapeutic gaps and laying the foundation for personalized treatment strategies in managing cryptococcal infections.

Key Market Players

  • Astellas Pharma Inc
  • Bristol-Myers Squibb Company
  • Glenmark Pharmaceuticals
  • Janssen Biotech Inc. (Johnson & Johnson Services, Inc.)
  • Novartis AG
  • Pfizer Inc
  • Asahi Kasei Pharma
  • Sigmapharm Laboratories LLC

Report Scope:

In this report, the Global Cryptococcosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cryptococcosis Therapeutics Market, By Treatment:

  • Amphotericin B
  • Flucytosine
  • Fluconazole
  • Other

Cryptococcosis Therapeutics Market, By Distribution Channel:

  • Hospitals
  • Retail Pharmacies
  • Specialty Clinics
  • Others

Cryptococcosis Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cryptococcosis Therapeutics Market.

Available Customizations:

Global Cryptococcosis Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cryptococcosis Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Amphotericin B, Flucytosine, Fluconazole, Others)
    • 5.2.2. By Distribution Channel (Hospitals, Retail Pharmacies, Specialty Clinics, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (Shares of Top 5 Market Players)
  • 5.3. Market Map
    • 5.3.1. By Treatment
    • 5.3.2. By Distribution Channel
    • 5.3.3. By Region

6. North America Cryptococcosis Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
      • 6.2.3.1. United States Cryptococcosis Therapeutics Market Outlook
        • 6.2.3.1.1. Market Size & Forecast
          • 6.2.3.1.1.1. By Value
        • 6.2.3.1.2. Market Share & Forecast
          • 6.2.3.1.2.1. By Treatment
          • 6.2.3.1.2.2. By Distribution Channel
      • 6.2.3.2. Canada Cryptococcosis Therapeutics Market Outlook
        • 6.2.3.2.1. Market Size & Forecast
          • 6.2.3.2.1.1. By Value
        • 6.2.3.2.2. Market Share & Forecast
          • 6.2.3.2.2.1. By Treatment
          • 6.2.3.2.2.2. By Distribution Channel
      • 6.2.3.3. Mexico Cryptococcosis Therapeutics Market Outlook
        • 6.2.3.3.1. Market Size & Forecast
          • 6.2.3.3.1.1. By Value
        • 6.2.3.3.2. Market Share & Forecast
          • 6.2.3.3.2.1. By Treatment
          • 6.2.3.3.2.2. By Distribution Channel

7. Europe Cryptococcosis Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
      • 7.2.3.1. France Cryptococcosis Therapeutics Market Outlook
        • 7.2.3.1.1. Market Size & Forecast
          • 7.2.3.1.1.1. By Value
        • 7.2.3.1.2. Market Share & Forecast
          • 7.2.3.1.2.1. By Treatment
          • 7.2.3.1.2.2. By Distribution Channel
      • 7.2.3.2. Germany Cryptococcosis Therapeutics Market Outlook
        • 7.2.3.2.1. Market Size & Forecast
          • 7.2.3.2.1.1. By Value
        • 7.2.3.2.2. Market Share & Forecast
          • 7.2.3.2.2.1. By Treatment
          • 7.2.3.2.2.2. By Distribution Channel
      • 7.2.3.3. United Kingdom Cryptococcosis Therapeutics Market Outlook
        • 7.2.3.3.1. Market Size & Forecast
          • 7.2.3.3.1.1. By Value
        • 7.2.3.3.2. Market Share & Forecast
          • 7.2.3.3.2.1. By Treatment
          • 7.2.3.3.2.2. By Distribution Channel
      • 7.2.3.4. Italy Cryptococcosis Therapeutics Market Outlook
        • 7.2.3.4.1. Market Size & Forecast
          • 7.2.3.4.1.1. By Value
        • 7.2.3.4.2. Market Share & Forecast
          • 7.2.3.4.2.1. By Treatment
          • 7.2.3.4.2.2. By Distribution Channel
      • 7.2.3.5. Spain Cryptococcosis Therapeutics Market Outlook
        • 7.2.3.5.1. Market Size & Forecast
          • 7.2.3.5.1.1. By Value
        • 7.2.3.5.2. Market Share & Forecast
          • 7.2.3.5.2.1. By Treatment
          • 7.2.3.5.2.2. By Distribution Channel

8. Asia Pacific Cryptococcosis Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
      • 8.2.3.1. China Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.1.1. Market Size & Forecast
          • 8.2.3.1.1.1. By Value
        • 8.2.3.1.2. Market Share & Forecast
          • 8.2.3.1.2.1. By Treatment
          • 8.2.3.1.2.2. By Distribution Channel
      • 8.2.3.2. India Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.2.1. Market Size & Forecast
          • 8.2.3.2.1.1. By Value
        • 8.2.3.2.2. Market Share & Forecast
          • 8.2.3.2.2.1. By Treatment
          • 8.2.3.2.2.2. By Distribution Channel
      • 8.2.3.3. South Korea Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.3.1. Market Size & Forecast
          • 8.2.3.3.1.1. By Value
        • 8.2.3.3.2. Market Share & Forecast
          • 8.2.3.3.2.1. By Treatment
          • 8.2.3.3.2.2. By Distribution Channel
      • 8.2.3.4. Japan Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.4.1. Market Size & Forecast
          • 8.2.3.4.1.1. By Value
        • 8.2.3.4.2. Market Share & Forecast
          • 8.2.3.4.2.1. By Treatment
          • 8.2.3.4.2.2. By Distribution Channel
      • 8.2.3.5. Australia Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.5.1. Market Size & Forecast
          • 8.2.3.5.1.1. By Value
        • 8.2.3.5.2. Market Share & Forecast
          • 8.2.3.5.2.1. By Treatment
          • 8.2.3.5.2.2. By Distribution Channel

9. South America Cryptococcosis Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
      • 9.2.3.1. Brazil Cryptococcosis Therapeutics Market Outlook
        • 9.2.3.1.1. Market Size & Forecast
          • 9.2.3.1.1.1. By Value
        • 9.2.3.1.2. Market Share & Forecast
          • 9.2.3.1.2.1. By Treatment
          • 9.2.3.1.2.2. By Distribution Channel
      • 9.2.3.2. Argentina Cryptococcosis Therapeutics Market Outlook
        • 9.2.3.2.1. Market Size & Forecast
          • 9.2.3.2.1.1. By Value
        • 9.2.3.2.2. Market Share & Forecast
          • 9.2.3.2.2.1. By Treatment
          • 9.2.3.2.2.2. By Distribution Channel
      • 9.2.3.3. Colombia Cryptococcosis Therapeutics Market Outlook
        • 9.2.3.3.1. Market Size & Forecast
          • 9.2.3.3.1.1. By Value
        • 9.2.3.3.2. Market Share & Forecast
          • 9.2.3.3.2.1. By Treatment
          • 9.2.3.3.2.2. By Distribution Channel

10. Middle East & Africa Cryptococcosis Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
      • 10.2.3.1. South Africa Cryptococcosis Therapeutics Market Outlook
        • 10.2.3.1.1. Market Size & Forecast
          • 10.2.3.1.1.1. By Value
        • 10.2.3.1.2. Market Share & Forecast
          • 10.2.3.1.2.1. By Treatment
          • 10.2.3.1.2.2. By Distribution Channel
      • 10.2.3.2. Saudi Arabia Cryptococcosis Therapeutics Market Outlook
        • 10.2.3.2.1. Market Size & Forecast
          • 10.2.3.2.1.1. By Value
        • 10.2.3.2.2. Market Share & Forecast
          • 10.2.3.2.2.1. By Treatment
          • 10.2.3.2.2.2. By Distribution Channel
      • 10.2.3.3. UAE Cryptococcosis Therapeutics Market Outlook
        • 10.2.3.3.1. Market Size & Forecast
          • 10.2.3.3.1.1. By Value
        • 10.2.3.3.2. Market Share & Forecast
          • 10.2.3.3.2.1. By Treatment
          • 10.2.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Treatment Launches

13. Competitive Landscape

  • 13.1. Astellas Pharma Inc
    • 13.1.1. Business Overview
    • 13.1.2. Company Snapshot
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As Reported)
    • 13.1.5. Recent Developments
    • 13.1.6. Key Personnel Details
    • 13.1.7. SWOT Analysis
  • 13.2. Bristol-Myers Squibb Company
  • 13.3. Glenmark Pharmaceuticals
  • 13.4. Janssen Biotech Inc.( Johnson & Johnson Services, Inc.)
  • 13.5. Novartis AG
  • 13.6. Pfizer Inc
  • 13.7. Asahi Kasei Pharma
  • 13.8. Sigmapharm Laboratories LLC

14. Strategic Recommendations

15. About us & Disclaimer